Radiation Oncology

  • In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...

  • Join Chris Toth, president, Oncology Systems Americas, for a look at Varian’s new product introductions and major initiatives highlighted at ASTRO this year:

  • Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central database and the Cloud. It offers full support throughout all of your QA, and enables you access to the different software modules and all of your data from one intuitive interface...

  • Somatom Confidence RT Pro, RT, radiation therapy, treatment planning

    December 20, 2016 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Siemens’ Somatom Confidence Radiation Therapy (RT) Pro computed tomography (CT) scanner with features dedicated to RT planning.

  • An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and...

targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study
News | Radiation Therapy | February 16, 2017

University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic...

ASTRO guideline, bone metastases, pallliative radiation therapy, gold standard
News | Radiation Therapy | February 14, 2017

February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical...

Accuray, Radixact treatment delivery system, TomoTherapy, Shonin approval, Japan
News | Radiation Therapy | February 13, 2017

February 13, 2017 — Accuray Inc.

ayDCE software, mpMRI, multiparametric magnetic resonance imaging, prostate MRI, RSNA 2017, AHRA, SIIM
Technology | Magnetic Resonance Imaging (MRI) | February 13, 2017

February 13, 2017 —  aycan recently introduced ayDCE software powered by aycan workstation.

state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey
News | Proton Therapy | February 10, 2017

Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state...

EGFR mutant lung cancer, brain metastases, order of treatment, radiation therapy, EGFR-directed drugs, Journal of Clinical Oncology study
News | Lung Cancer | February 09, 2017

February 9, 2017 — A study published in the...

IBA, Dolphin Online Ready Patient QA and Monitoring solution, radiotherapy, North West Cancer Centre, Londonderry, Northern Ireland, first in U.K.
News | Radiation Therapy | February 07, 2017

IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its Dolphin Online Ready...

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017

Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will...

Institut Curie, Onxeo, radiotherapy, immunotherapy, DNA repair inhibitors, AsiDNA, DBait
News | Radiation Therapy | February 06, 2017

Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed at investigating...

radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017

A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...

recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine
News | Prostate Cancer | February 03, 2017

Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with...

insightec exablate high intensity focused ultrasound system

The InSightec ExAblate focused ultrasound system developed to treat essential tremor. Studies are underway to see if FUS can be used to treat other brain conditions and brain cancer.

Feature | Focused Ultrasound Therapy | February 03, 2017 | Dave Fornell

Focused ultrasound (FUS), also called high-intensity focused ultrasound (HIFU), has gained a lot of interest in...

ASTRO, lawmakers, healthcare access, insurance coverage, Congress, radiation therapy
News | Radiation Therapy | February 03, 2017

As the new Congress and administration wrestle with policy decisions on the provision of high-quality, affordable...

PET/CT, primary and metastatic prostate cancer, Journal of Nuclear Medicine study, JNM

Ga-68-BBN PET/CT of a 64-year-old man newly diagnosed with prostate cancer by biopsy. Multiple bone metastasis lesions (arrows) were detected. Image courtesy of Jingjing Zhang, Peking Union Medical College, Beijing, China.

News | Prostate Cancer | February 02, 2017

In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the...

RayStation 6, new release, RaySearch Laboratories, radiation therapy, treatment planning, TomoTherapy
Technology | Treatment Planning | February 01, 2017

RayStation 6, the latest release of RaySearch’s radiation therapy treatment planning system, adds significant new...

oncology analytics

Mosaiq Oncology Analytics is a cloud-based solution that integrates with multiple systems, so the user can leverage the information within and beyond the oncology department.

Feature | Radiation Oncology | February 01, 2017 | By Rachael Bennett, BHS, R.T.(R)(T)

In 2016, the America Cancer Society expected 1,685,210 new cancer diagnoses in the United States alone. And...

RayStation, radiation therapy, treatment planning system, University of Wisconsin Madison
News | Treatment Planning | January 30, 2017

The Department of Human Oncology at the University of Wisconsin-Madison has chosen RayStation as its next radiation...

Mevion S250 proton therapy system, UF Health Cancer Center - Orlando Health, Airo CT scanner, Veritiy Patient Positioning System, radiation therapy
News | Proton Therapy | January 27, 2017

Mevion Medical Systems and UF Health Cancer Center - Orlando Health recently announced the first patient treatment...

Accuray, Radixact Treatment Delivery System, Miami Cancer Institute, first patients
News | Radiation Therapy | January 26, 2017

Accuray Inc. announced recently that Miami Cancer Institute, a part of Baptist Health South Florida, is now treating...

Overlay Init